2025
Factors associated with decreased treatment intensity in patients with metastatic colon cancer: A real world analysis.
Forman R, Wang R, Yasin F, Kwaramba T, Lacy J, Ma X, Dinan M. Factors associated with decreased treatment intensity in patients with metastatic colon cancer: A real world analysis. Journal Of Clinical Oncology 2025, 43: 11168-11168. DOI: 10.1200/jco.2025.43.16_suppl.11168.Peer-Reviewed Original ResearchMetastatic colon cancerNon-intensive therapyNational Comprehensive Cancer NetworkPoor performance statusIntensive therapyFlatiron Health electronic health record-derived deidentified databaseColon cancerIntensive first-line therapyUndertreatment of older patientsNational Comprehensive Cancer Network guidelinesOdds ratioAssociated with treatment choiceFirst-line therapyAssociated with female sexComprehensive Cancer NetworkRetrospective cohort studyYear of diagnosisShorter overall survivalNon-frail patientsOlder ageNon-frailMultivariate logistic regressionEstimate odds ratiosAssociated with receiptTreatment intensity
2024
Evaluation and Surgical Management of Pediatric Cutaneous Melanoma and Atypical Spitz and Non-Spitz Melanocytic Tumors (Melanocytomas): A Report From Children's Oncology Group
Sargen M, Barnhill R, Elder D, Swetter S, Prieto V, Ko J, Bahrami A, Gerami P, Karunamurthy A, Pappo A, Schuchter L, LeBoit P, Yeh I, Kirkwood J, Jen M, Dunkel I, Durham M, Christison-Lagay E, Austin M, Aldrink J, Mehrhoff C, Hawryluk E, Chu E, Busam K, Sondak V, Messina J, Puig S, Colebatch A, Coughlin C, Berrebi K, Laetsch T, Mitchell S, Seynnaeve B. Evaluation and Surgical Management of Pediatric Cutaneous Melanoma and Atypical Spitz and Non-Spitz Melanocytic Tumors (Melanocytomas): A Report From Children's Oncology Group. Journal Of Clinical Oncology 2024, 43: 1157-1167. PMID: 39365959, PMCID: PMC11908957, DOI: 10.1200/jco.24.01154.Peer-Reviewed Original ResearchSentinel lymph node biopsyAtypical Spitz tumorsCutaneous melanomaSpitz tumorsRe-ExcisionSurgical managementMelanocytic tumorsSurgical management of cutaneous melanomaManagement of cutaneous melanomaNational Comprehensive Cancer Network guidelinesLymph node biopsyDefinitive surgical treatmentProgression to CMChildren's Oncology GroupDiagnosis of CMNode biopsyExcisional biopsyOncology GroupMalignant potentialSurgical treatmentNetwork guidelinesBiopsyClinicopathological evaluationCohort studyMelanocytic neoplasmsCharacterization of accelerated approval status, trial endpoints and results, and recommendations in guidelines for oncology drug treatments from the National Comprehensive Cancer Network: cross sectional study
Mooghali M, Mitchell A, Skydel J, Ross J, Wallach J, Ramachandran R. Characterization of accelerated approval status, trial endpoints and results, and recommendations in guidelines for oncology drug treatments from the National Comprehensive Cancer Network: cross sectional study. BMJ Medicine 2024, 3: e000802. PMID: 38596814, PMCID: PMC11002412, DOI: 10.1136/bmjmed-2023-000802.Peer-Reviewed Original ResearchNational Comprehensive Cancer NetworkNational Comprehensive Cancer Network guidelinesComprehensive Cancer NetworkFood and Drug AdministrationCancer NetworkUS Food and Drug AdministrationCategories of evidenceAccelerated approvalCross sectional studyDrug treatmentConfirmatory trialsClinical benefitTrial resultsOncological indicationsTraditional approvalGuideline recommendationsOutcome measuresSectional studyApproval statusFDA decisionRecommended alignmentOncologyUpdate recommendationsPostapproval trialsGuidelines
2023
Factors associated with the use of adjuvant radiation therapy in stage III melanoma
King A, Lee V, Yu B, Mirza F, Zogg C, Yang D, Tran T, Leventhal J, An Y. Factors associated with the use of adjuvant radiation therapy in stage III melanoma. Frontiers In Oncology 2023, 13: 1005930. PMID: 36816935, PMCID: PMC9929351, DOI: 10.3389/fonc.2023.1005930.Peer-Reviewed Original ResearchAdjuvant radiation therapyStage III melanomaNational Cancer Data BaseRadiation therapyPositive nodesNational Comprehensive Cancer Network guidelinesUse of RTUtilization of RTMultivariable logistic regression analysisPalliative intent therapyDistant metastatic diseasePrimary treatment modalityMajority of patientsMicroscopic residual tumorHospital-specific factorsMultivariable regression analysisLogistic regression analysisRegression analysisMetastatic diseaseOverall cohortResidual tumorDisease benefitNetwork guidelinesPalliative careMean age
2022
Extended versus standard pelvic lymph node dissection yields no difference in 3-year biochemical recurrence rates
Nagaya N, Chua K, Sterling J, Horie S, Kim I. Extended versus standard pelvic lymph node dissection yields no difference in 3-year biochemical recurrence rates. Prostate International 2022, 11: 107-112. PMID: 37409090, PMCID: PMC10318318, DOI: 10.1016/j.prnil.2022.12.005.Peer-Reviewed Original ResearchStandard pelvic lymph node dissectionPelvic lymph node dissectionLymph node dissectionNode-positive patientsNode dissectionAdjuvant treatmentRecurrence rateGleason scoreSubgroup analysisNational Comprehensive Cancer Network guidelinesPSA progression-free survivalAdjuvant androgen deprivation therapyPSA recurrence rateAndrogen deprivation therapyNode-positive diseaseProgression-free survivalGleason score 8Kaplan-Meier analysisAdditional therapeutic benefitBiochemical recurrence ratePositive prostate cancerGleason score 6Time of prostatectomyDeprivation therapyMedian followPre-Treatment Staging Imaging in Rectal Cancer: Results From the Quality Oncology Practice Initiative
Chen RC, Garrett-Mayer E, Kamal AH, Makhoul I, Kozlik MMP, Crist STS, Chiang AC, Force O. Pre-Treatment Staging Imaging in Rectal Cancer: Results From the Quality Oncology Practice Initiative. JCO Oncology Practice 2022, 18: e1367-e1373. PMID: 35353546, DOI: 10.1200/op.21.00455.Peer-Reviewed Original ResearchConceptsQuality Oncology Practice InitiativeRectal cancerTime pointsASCO's Quality Oncology Practice InitiativeNational Comprehensive Cancer Network guidelinesPelvic magnetic resonance imagingNonmetastatic rectal cancerPre-treatment stagingThird of patientsAssessment time pointsRandom-effects modelMagnetic resonance imagingPractice initiativesSubsequent time pointsQuality improvement effortsInitial therapyInitial stagingAppropriate imagingStaging scansNetwork guidelinesUnique patientsOptimal treatmentCare coordinationN stagingEndorectal ultrasoundGenetic testing in prostate cancer management: Considerations informing primary care
Giri V, Morgan T, Morris D, Berchuck J, Hyatt C, Taplin M. Genetic testing in prostate cancer management: Considerations informing primary care. CA A Cancer Journal For Clinicians 2022, 72: 360-371. PMID: 35201622, DOI: 10.3322/caac.21720.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNational Comprehensive Cancer Network guidelinesProstate cancerPrimary careGenetic testingNetwork guidelinesFamily historyClinical trial optionsGermline genetic testingMetastatic prostate cancerPrimary care providersMultidisciplinary patient careProstate cancer managementRole of cliniciansHereditary cancer riskMultiple professional societiesComprehensive family historyPC survivorsGermline testingPC screeningAggressive diseasePoor outcomePC careClinical pathwayCancer managementCancer riskProlonging utilization of systemic therapy in oligoprogressive metastatic renal cell carcinoma using stereotactic body radiation therapy.
Muddasani R, Govindarajan A, Salgia S, Salgia N, Zengin Z, Meza L, Hsu J, Chehrazi-Raffle A, Dizman N, Chawla N, Malhotra J, Bergerot C, Philip E, Castro D, Dandapani S, Tripathi N, Sayegh N, Pal S. Prolonging utilization of systemic therapy in oligoprogressive metastatic renal cell carcinoma using stereotactic body radiation therapy. Journal Of Clinical Oncology 2022, 40: 336-336. DOI: 10.1200/jco.2022.40.6_suppl.336.Peer-Reviewed Original ResearchSystemic therapyNational Comprehensive Cancer Network guidelinesMetastatic renal cell carcinomaStereotactic body radiation therapyMedian total doseClear cell histologyFirst-line therapyFrequent side effectsLines of therapyPreponderance of patientsRetrospective data collectionBody radiation therapyRenal cell carcinomaEfficacy of radiotherapyMRCC patientsMedian doseCell histologyNew regimensSystemic treatmentClinicopathologic characteristicsRT toxicityClinical benefitNetwork guidelinesSame therapyCell carcinomaPractice Patterns and Real-Life Outcomes for Patients with Acute Promyelocytic Leukemia in the United States
Bewersdorf JP, Prozora S, Podoltsev NA, Shallis R, Huntington SF, Neparidze N, Wang R, Zeidan AM, Davidoff AJ. Practice Patterns and Real-Life Outcomes for Patients with Acute Promyelocytic Leukemia in the United States. Blood Advances 2022, 6: 376-385. PMID: 34724703, PMCID: PMC8791583, DOI: 10.1182/bloodadvances.2021005642.Peer-Reviewed Original ResearchConceptsAcute promyelocytic leukemiaAdverse outcomesPromyelocytic leukemiaNational Comprehensive Cancer Network guidelinesBaseline white blood cell countFavorable long-term prognosisWhite blood cell countVizient Clinical Data BaseGuideline-concordant regimensGuideline-concordant therapyGuideline-concordant treatmentGuideline-recommended therapiesBaseline clinical characteristicsHigh-risk diseaseLong-term prognosisPopulation-based registryBlood cell countClinical data baseLarge database analysisLogistic regression modelsTreatment concordanceClinical characteristicsReal-world practiceTreatment patternsNetwork guidelines
2020
Variations in recommended surveillance in colorectal cancer survivorship care plans.
Chodoff A, Smith K, Shukla A, Blackford A, Ahuja N, Johnston F, Peairs K, Ngaiza J, Warczynski T, Nettles B, Stotsky-Himelfarb E, Murphy A, Mayonado N, DeSanto J, Snyder C, Choi Y. Variations in recommended surveillance in colorectal cancer survivorship care plans. Journal Of Clinical Oncology 2020, 38: 13-13. DOI: 10.1200/jco.2020.38.29_suppl.13.Peer-Reviewed Original ResearchAmerican Cancer SocietyCancer CenterCancer riskNational Comprehensive Cancer Network guidelinesTreatment-related side effectsCancer survivorship care plansGuideline-concordant recommendationsGenetic counseling/testingSurvivorship care plansCommunity cancer centerCRC survivorsPatient demographicsEntire cohortNetwork guidelinesCRC diagnosisTreatment detailsSurveillance modalitiesCancer stageCancer SocietyCare plansHealth promotionClinical OncologySide effectsCancer diagnosisAmerican Society
2019
Genetic Testing for Breast Cancer Susceptibility Should Be Offered before Unilateral Abdominally Based Free Flap Breast Reconstruction.
Dayan E, Chittenden A, Garber J, Wo L, Caterson S, Carty M, Erdmann-Sager J. Genetic Testing for Breast Cancer Susceptibility Should Be Offered before Unilateral Abdominally Based Free Flap Breast Reconstruction. Plastic & Reconstructive Surgery 2019, 144: 12-20. PMID: 31246791, DOI: 10.1097/prs.0000000000005693.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAtaxia Telangiectasia Mutated ProteinsBRCA2 ProteinBreast NeoplasmsCheckpoint Kinase 2Delivery of Health CareFanconi Anemia Complementation Group ProteinsFemaleFree Tissue FlapsGenetic Predisposition to DiseaseGenetic TestingHumansMammaplastyMastectomyMiddle AgedMutationRetrospective StudiesRNA HelicasesUbiquitin-Protein LigasesConceptsFree flap breast reconstructionFlap breast reconstructionBreast reconstructionGenetic testingDecreasing cost of genetic testingCost of genetic testingNational Comprehensive Cancer Network guidelinesWomen's Hospital/Dana-Farber Cancer InstitutePathogenic mutationsBreast cancer susceptibilityDeleterious genetic mutationsPercentage of patientsFollow-up periodHospital financial dataContralateral mastectomyContralateral surgeryATM mutationsCancer susceptibilityCost-effectiveNetwork guidelinesChart reviewInclusion criteriaBreast cancerFollow-upClinical dataGender disparities in head and neck cancer chemotherapy clinical trials participation and treatment
Benchetrit L, Torabi SJ, Tate JP, Mehra S, Osborn HA, Young MR, Burtness B, Judson BL. Gender disparities in head and neck cancer chemotherapy clinical trials participation and treatment. Oral Oncology 2019, 94: 32-40. PMID: 31178210, DOI: 10.1016/j.oraloncology.2019.05.009.Peer-Reviewed Original ResearchConceptsChemotherapy clinical trialsNational Cancer DatabaseClinical trialsDefinitive radiotherapyChemotherapy administrationNational Comprehensive Cancer Network guidelinesMultivariable logistic regression analysisNeck squamous cell carcinomaEnd Results ProgramSquamous cell carcinomaClinical trial participationLogistic regression analysisGeneral U.S. populationChemotherapy useDefinitive chemoradiotherapyNCCN guidelinesAdult patientsDefinitive treatmentMultivariable analysisNetwork guidelinesResults ProgramCell carcinomaTrial participationCancer DatabaseU.S. patientsMulti-modality Treatment and Survival in Sinonasal Minor Salivary Gland Tumors
Torabi SJ, Spock T, Cardoso B, Chao J, Manes RP, Judson BL. Multi-modality Treatment and Survival in Sinonasal Minor Salivary Gland Tumors. Journal Of Neurological Surgery Part B Skull Base 2019, 81: 198-205. PMID: 32206540, PMCID: PMC7082160, DOI: 10.1055/s-0039-1683437.Peer-Reviewed Original ResearchMinor salivary gland tumorsSalivary gland tumorsTriple-modality therapyGland tumorsModality therapyMultimodality treatmentPositive marginsTreatment modalitiesSubset analysisNational Comprehensive Cancer Network guidelinesClinical American Joint CommitteeNational Cancer DatabaseMulti-modality treatmentOnly treatment modalityAmerican Joint CommitteeMost treatment modalitiesAdjuvant chemoradiotherapySurvival benefitSurgical managementNetwork guidelinesCancer DatabaseChemoradiotherapyCommon treatmentSurgeryJoint CommitteeClinically node-negative head and neck mucosal melanoma: An analysis of current treatment guidelines & outcomes
Torabi SJ, Benchetrit L, Spock T, Cheraghlou S, Judson BL. Clinically node-negative head and neck mucosal melanoma: An analysis of current treatment guidelines & outcomes. Oral Oncology 2019, 92: 67-76. PMID: 31010627, DOI: 10.1016/j.oraloncology.2019.03.017.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overCombined Modality TherapyDatabases, FactualDisease ManagementFemaleHead and Neck NeoplasmsHumansKaplan-Meier EstimateLymph NodesMaleMelanomaMiddle AgedMucous MembraneNeoplasm StagingPractice Guidelines as TopicPractice Patterns, Physicians'PrognosisProportional Hazards ModelsTreatment OutcomeYoung AdultConceptsElective neck dissectionMajority of patientsSinonasal cavityMM casesNCCN guidelinesNational Comprehensive Cancer Network guidelinesNeck mucosal melanomaNode-negative headNational Cancer DatabaseCurrent treatment guidelinesImproved OSRT utilizationSN patientsNCCN recommendationsNeck dissectionMM patientsMucosal melanomaTreatment guidelinesTreatment patternsNetwork guidelinesCancer DatabaseRetrospective analysisOral cavityPatientsSurvival ratePractice Patterns and Guideline Non-Adherence in Surgical Management of Appendiceal Carcinoid Tumors
Heller DR, Jean RA, Luo J, Kurbatov V, Grisotti G, Jacobs D, Chiu AS, Zhang Y, Khan SA. Practice Patterns and Guideline Non-Adherence in Surgical Management of Appendiceal Carcinoid Tumors. Journal Of The American College Of Surgeons 2019, 228: 839-851. PMID: 30898583, PMCID: PMC6751559, DOI: 10.1016/j.jamcollsurg.2019.02.050.Peer-Reviewed Original ResearchConceptsNational Comprehensive Cancer Network guidelinesAge 65 yearsAppendiceal carcinoid tumorsAppendiceal carcinoidsLarge tumorsPractice patternsOverall survivalCarcinoid tumorsSurgical managementNetwork guidelinesProcedure typeSmall tumorsHistory of malignancyNational Cancer DatabaseNational practice patternsMultivariable logistic regressionImpact of guidelinesCox proportional hazardsAggressive resectionLymphovascular invasionClinical factorsTreatment guidelinesTumor sizePatient groupNon-adherence
2018
Disconnect between physical activity guidelines and ground reality: A real world analysis of physical activity profile of cancer survivors.
Algotar A, Algotar K, Berkowitz A, Sanft T. Disconnect between physical activity guidelines and ground reality: A real world analysis of physical activity profile of cancer survivors. Journal Of Clinical Oncology 2018, 36: 105-105. DOI: 10.1200/jco.2018.36.7_suppl.105.Peer-Reviewed Original ResearchPhysical activity guidelinesCancer survivorsPhysical activityActivity guidelinesReal-world analysisNational Comprehensive Cancer Network guidelinesCurrent physical activity guidelinesPhysical activity weeklySurvivorship care plansPercent of survivorsPhysical activity recommendationsComprehensive cancer centerPhysical activity profilesNCCN guidelinesSurvivorship clinicSurvivorship guidelinesNetwork guidelinesType patientsCancer CenterActivity recommendationsProstate cancerCare plansCurrent recommendationsNumber of visitsCancer typesMolecular imaging of prostate cancer
Boustani AM, Pucar D, Saperstein L. Molecular imaging of prostate cancer. British Journal Of Radiology 2018, 91: 20170736. PMID: 29243485, PMCID: PMC5966010, DOI: 10.1259/bjr.20170736.Peer-Reviewed Original ResearchConceptsProstate cancerNational Comprehensive Cancer Network guidelinesMetastatic diseaseMolecular imagingCommon malignancyNetwork guidelinesEffective treatmentMolecular imaging techniquesCancerMetabolic intermediaryTreatmentImaging techniquesRelevant radiotracersImagingTimely detectionAccurate imagingChemotherapySurgeryRecurrenceMalignancyDiseaseReceptors
2017
Impacts of Early Guideline-Directed 21-Gene Recurrence Score Testing on Adjuvant Therapy Decision Making
Dzimitrowicz H, Mougalian S, Storms S, Hurd S, Chagpar AB, Killelea BK, Horowitz NR, Lannin DR, Harigopal M, Hofstatter E, DiGiovanna MP, Adelson KB, Silber A, Abu-Khalaf M, Chung G, Zaheer W, Abdelghany O, Hatzis C, Pusztai L, Sanft TB. Impacts of Early Guideline-Directed 21-Gene Recurrence Score Testing on Adjuvant Therapy Decision Making. JCO Oncology Practice 2017, 13: jop.2017.022731. PMID: 29048991, DOI: 10.1200/jop.2017.022731.Peer-Reviewed Original ResearchConceptsAdjuvant therapy decisionsRecurrence scoreChemotherapy useRS testingMedical oncologistsHistorical controlsChemotherapy decisionsTherapy decisionsEligibility criteriaNational Comprehensive Cancer Network guidelinesProspective quality improvement projectEarly-stage breast cancerAdjuvant chemotherapy recommendationsTime of diagnosisTime of surgeryQuality improvement projectTesting groupChemotherapy initiationChemotherapy recommendationsMedian timeTrial enrollmentNetwork guidelinesSurgical oncologistsClinical trialsBreast cancerAdjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non–Small-Cell Lung Cancer
Woodard GA, Wang SX, Kratz JR, Zoon-Besselink CT, Chiang CY, Gubens MA, Jahan TM, Blakely CM, Jones KD, Mann MJ, Jablons DM. Adjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non–Small-Cell Lung Cancer. Clinical Lung Cancer 2017, 19: 58-64. PMID: 28645632, DOI: 10.1016/j.cllc.2017.05.015.Peer-Reviewed Original ResearchConceptsHigh-risk patientsDisease-free survivalLow-risk patientsAdjuvant chemotherapyNational Comprehensive Cancer Network guidelinesCell lung cancer patientsMolecular profilingEarly-stage NSCLCHigh-risk criteriaLog-rank analysisCell lung cancerHigh-risk designationLung cancer patientsKaplan-Meyer estimatesAdjuvant treatmentNonsquamous NSCLCOccult metastasesStage IAStage NSCLCAdjuvant interventionClinicopathologic characteristicsComplete resectionConsecutive patientsDisease recurrenceNCCN criteriaOncoKB: A Precision Oncology Knowledge Base
Chakravarty D, Gao J, Phillips S, Kundra R, Zhang H, Wang J, Rudolph JE, Yaeger R, Soumerai T, Nissan MH, Chang MT, Chandarlapaty S, Traina TA, Paik PK, Ho AL, Hantash FM, Grupe A, Baxi SS, Callahan MK, Snyder A, Chi P, Danila D, Gounder M, Harding JJ, Hellmann MD, Iyer G, Janjigian Y, Kaley T, Levine DA, Lowery M, Omuro A, Postow MA, Rathkopf D, Shoushtari AN, Shukla N, Voss M, Paraiso E, Zehir A, Berger MF, Taylor BS, Saltz LB, Riely GJ, Ladanyi M, Hyman DM, Baselga J, Sabbatini P, Solit DB, Schultz N. OncoKB: A Precision Oncology Knowledge Base. JCO Precision Oncology 2017, 2017: 1-16. PMID: 28890946, PMCID: PMC5586540, DOI: 10.1200/po.17.00011.Peer-Reviewed Original ResearchPrecision oncology knowledge baseNational Comprehensive Cancer Network guidelinesMolecular alterationsProspective clinical sequencingSomatic molecular alterationsDrug Administration labelingLevel of evidenceSpecific molecular alterationsOptimal treatment decisionsClinical support toolPrimary tumor samplesIndividual somatic mutationsEvidence-based informationExpert group recommendationsClinical benefitNetwork guidelinesActionable alterationsCancer carePotential treatment implicationsStandard treatmentTreatment decisionsPatient tumorsCancer-associated genesPredictive significanceUS Food
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply